Abigail Herron from Aviva Investors describes why AMR is a blind spot for investors and which action is needed...
OPINION
Experts Point of View
SPCs offer up to five and a half years of additional protection after patent expiration for pharmaceuticals...
Prior to Danish Genmab A/S’s recent licence option deal with AbbVie Inc, Rentschler Biopharma has extended...
If reopening the economy after the prolonged shutdown was the end of the beginning, then the successful...
Intellectual Property Providing access to medicines at affordable prices while maintaining incentives for the...
Immatics Biotechnologies has landed a potential US$1.1bn deal with GlaxoSmithKline (GSK) to find novel cancer...
Share
